INCY - Incyte Corp - SEC Form 4 Insider Trading Screener

Services - Engineering, Accounting, Research, Management Services - Commercial Physical & Biological Research - INCY (879169)
General
Tickers
Insider
Sh Price $
Lqdty M$
Date
Filing Date
  
Trade Date
  
Filing Delay
N Days Ago
Transaction Filing
P - Purchase
S - Sale
A - Grant
D - Sale to Iss
G - Gift
F - Tax
M - Option Ex
X - Option Ex
C - Cnv Deriv
W - Inherited
No deriv Multiple Days
Traded K$
Own Chg %
Industry
Insider Title   Officer
    COB
    CEO
    Pres
    COO
    CFO
    GC
    VP
  Director
  10% Own
  Other
Group by
Sort by
Max Results
Page
clear
51 results - Yahoo - Google - Finviz - Stockcharts - Tradingview - Stocktwits - SEC
TCcnt1d1w1m6m
P6+2+0-1+16
S45-1-2-3-9

X

Filing Date

Trade Date

Ticker

Insider Name

Insider Title

Trade Type 

Share Price

Shares Traded

Shares Owned

Own chg

Value Traded

1d ret

1w ret

1m ret

6m ret

2017-04-13
INCYBienaime Jean JacquesDirP - Purchase$139.66+1,0003,177+46%+$139,6600-2
D
2017-04-07
INCYStein Steven HEVP, Chief Medical OfficerS - Sale+OE$137.88-32,00014,648-69%-$4,412,310+2-7
D
2017-04-10
INCYSiegel Eric H.EVP, GCS - Sale+OE$140.18-4,04316,785-19%-$566,748+2-7
D
2017-04-10
INCYGryska David WEVP, CFOS - Sale+OE$138.00-41,52819,015-69%-$5,730,864+2-7
2017-04-07
INCYBienaime Jean JacquesDirP - Purchase$139.48+1,0002,177+85%+$139,480+2-7
D
2017-03-17
INCYBrooke Paul ADirS - Sale+OE$147.75-20,000196,756-9%-$2,955,000-5-6-15
DM
2017-03-16
INCYFriedman Paul ADirS - Sale+OE$148.72-50,000297,518-14%-$7,436,164-5-6-15
2017-02-27
INCYHuber Reid MEVP, Chief Scientific OfficerS - Sale$131.88-2,00852,262-4%-$264,81500+5
D
2017-02-23
INCYFriedman Paul ADirS - Sale+OE$120.32-50,000297,518-14%-$6,016,000-1+2+4
2017-01-09
INCYHuber Reid MEVP, Chief Scientific OfficerS - Sale$113.55-11,73952,185-18%-$1,332,963+20+6
D
2016-11-15
INCYSwain Paula JEVP, HRS - Sale+OE$103.26-10,00029,248-25%-$1,032,600-2+1-3
2016-11-09
INCYHuber Reid MEVP, Chief Scientific OfficerS - Sale$109.95-2,71563,924-4%-$298,5140-4-4
D
2016-10-20
INCYSwain Paula JEVP, HRS - Sale+OE$90.00-10,00029,248-25%-$900,000-1-1+23+41
D
2016-10-07
INCYHuber Reid MEVP, Chief Scientific OfficerS - Sale+OE$96.40-11,70966,601-15%-$1,128,748-2-60+46
D
2016-10-07
INCYFlannelly Barry PEVP, GM USS - Sale+OE$97.00-24,20411,187-68%-$2,347,788-2-60+46
D
2016-09-23
INCYSwain Paula JEVP, HRS - Sale+OE$90.00-20,00029,248-41%-$1,800,0000+6-1+57
2016-08-02
INCYHuber Reid MEVP, Chief Scientific OfficerS - Sale$87.96-10,00066,601-13%-$879,600+2-1-9+36
D
2016-07-29
INCYSwain Paula JEVP, HRS - Sale+OE$90.00-60,00029,248-67%-$5,400,000+2-1-9+36
DM
2016-03-15
INCYBaker JulianDir, 10%P - Purchase$63.98+800,00020,423,396+4%+$51,184,194+3+7+23+27
M
2016-02-24
INCYBaker JulianDir, 10%P - Purchase$70.79+64,29019,681,9630%+$4,550,987-1-2-8+11
M
2016-02-12
INCYBaker JulianDir, 10%P - Purchase$69.87+887,16519,624,181+5%+$61,983,797+4+3-9+14
M
2016-02-11
INCYBaker JulianDir, 10%P - Purchase$63.53+2,251,42718,824,191+14%+$143,029,696+4+3-9+14
D
2016-01-15
INCYSwain Paula JEVP, HRS - Sale+OE$76.96-13,53123,693-36%-$1,041,346-1+2-4+12
D
2016-01-06
INCYLevy Richard SEVP, Chief Drug Dev OfficerS - Sale+OE$101.86-3,93716,926-19%-$401,023-3-14-25-10
D
2015-12-10
INCYSiegel Eric H.EVP, GCS - Sale+OE$107.96-1,9363,710-34%-$209,011+5+4-29-28
D
2015-12-07
INCYLevy Richard SEVP, Chief Drug Dev OfficerS - Sale+OE$106.18-3,93716,926-19%-$418,031+2+6-12-24
DM
2015-11-17
INCYFriedman Paul ADirS - Sale+OE$113.83-225,000297,518-43%-$25,612,109-3-1-3-33
D
2015-11-10
INCYSiegel Eric H.EVP, GCS - Sale+OE$104.86-2,2223,710-37%-$232,999+3+12+2-29
D
2015-11-06
INCYLevy Richard SEVP, Chief Drug Dev OfficerS - Sale+OE$116.51-3,93616,926-19%-$458,583-3-1-1-36
D
2015-11-03
INCYWenqing YaoEVP, Discovery Medicinal, PS - Sale+OE$124.78-5,78621,371-21%-$721,961-14-9-7-39
D
2015-10-13
INCYSiegel Eric H.EVP, GCS - Sale+OE$101.49-2,2223,355-40%-$225,511-4-5-8-33
D
2015-10-06
INCYLevy Richard SEVP, Chief Drug Dev OfficerS - Sale+OE$122.29-3,93716,926-19%-$481,456+2+2+12-24
D
2015-09-21
INCYHuber Reid MEVP, Chief Scientific OfficerS - Sale+OE$124.29-10,00062,865-14%-$1,242,900-4-14-8-42
D
2015-09-16
INCYSiegel Eric H.EVP, GCS - Sale+OE$130.69-2,2223,355-40%-$290,393-6-11-14-47
2015-09-11
INCYLevy Richard SEVP, Chief Drug Dev OfficerS - Sale$130.00-4,30116,926-20%-$559,1300-10-24-51
D
2015-09-08
INCYLevy Richard SEVP, Chief Drug Dev OfficerS - Sale+OE$118.90-3,93721,227-16%-$468,109+5+5-18-47
D
2015-08-13
INCYSiegel Eric H.EVP, GCS - Sale+OE$107.69-2,2223,355-40%-$239,287-1-10+16-41
D
2015-08-06
INCYLevy Richard SEVP, Chief Drug Dev OfficerS - Sale+OE$111.95-3,93621,227-16%-$440,6350+2+16-32
DM
2015-07-14
INCYWenqing YaoEVP, Discovery Medicinal, PS - Sale+OE$116.70-12,85021,539-37%-$1,499,538-1-3-8-34
D
2015-07-14
INCYSiegel Eric H.EVP, GCS - Sale+OE$113.61-2,2223,355-40%-$252,441-1-3-8-34
D
2015-07-15
INCYLevy Richard SEVP, Chief Drug Dev OfficerS - Sale+OE$120.00-70,21721,227-77%-$8,426,040-1-3-8-34
D
2015-07-06
INCYLevy Richard SEVP, Chief Drug Dev OfficerS - Sale+OE$107.00-3,93721,227-16%-$421,259+2+11+5-2
D
2015-06-23
INCYDaly James MEVP, Chief Commercial OfficerS - Sale+OE$108.24-11,6913,521-77%-$1,265,47000+4+4
D
2015-06-19
INCYLevy Richard SEVP, Chief Drug Dev OfficerS - Sale+OE$108.13-20,00021,227-49%-$2,162,600-4-8+5+4
D
2015-06-12
INCYSiegel Eric H.EVP, GCS - Sale+OE$105.31-2,2233,355-40%-$234,104+1+5+11+2
D
2015-06-08
INCYLevy Richard SEVP, Chief Drug Dev OfficerS - Sale+OE$107.58-3,93721,227-16%-$423,542+1-1+2+2
DM
2015-05-26
INCYFriedman Paul ADirS - Sale+OE$107.22-196,751297,518-40%-$21,096,678+2+1-3+4
D
2015-05-26
INCYDaly James MEVP, Chief Commercial OfficerS - Sale+OE$106.39-12,0933,521-77%-$1,286,636+2+1-3+4
DM
2015-05-21
INCYFriedman Paul ADirS - Sale+OE$108.22-102,243297,518-26%-$11,064,921+1+2+2+8
D
2015-05-14
INCYSiegel Eric H.EVP, GCS - Sale+OE$104.99-2,2223,355-40%-$233,288+1+1-3-1
D
2015-05-06
INCYLevy Richard SEVP, Chief Drug Dev OfficerS - Sale+OE$99.43-7,41221,227-26%-$736,975+1+3+3+13

AAmended filing
DDerivative transaction in filing (usually option exercise)
EError detected in filing
MMultiple transactions in filing; earliest reported transaction date and weighted average transaction price
S - SaleSale of securities on an exchange or to another person
S - Sale+OESale of securities on an exchange or to another person (after option exercise)
F - TaxPayment of exercise price or tax liability using portion of securities received from the company
P - PurchasePurchase of securities on an exchange or from another person
Return to top